Treatment comparison
Eczema treatments compared: steroid and non-steroid creams, side by side
Reviewed by Dr [PLACEHOLDER], Dermatologist.
Last checked [PLACEHOLDER date].
A plain comparison to help you talk to your dermatologist. Treatment choices depend on eczema severity, where flare-ups happen, your age, and past response to topical steroids.
Some are steroid creams. Some are non-steroid eczema creams, such as tacrolimus, pimecrolimus, crisaborole and ruxolitinib. Tablets and injections are kept for more severe atopic dermatitis. Compare how strong each one is and where on the body it can be used.
Safety note
Differences in cutaneous atrophy (skin thinning) risk are clinically significant when contrasting prolonged corticosteroid use against non-steroidal modalities. Agents including ruxolitinib, crisaborole, and calcineurin inhibitors do not induce collagen degradation in sensitive or intertriginous zones.
Summary
Comparison table
Displaying 5 treatment types across 6 key factors
| Modality / Metric | 1. Steroid Creams Topical Corticosteroid | 2. Tacrolimus / Pimecrolimus Calcineurin Inhibitors | 3. Crisaborole Topical PDE4 Inhibitor | 4. Ruxolitinib Cream Topical JAK Inhibitor | 5. Biologics & Oral JAKs Systemic Immunomodulators |
|---|---|---|---|---|---|
| Severity it is used for | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | Mild to moderate | [PLACEHOLDER] |
| Age from | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | Age 2+ (FDA approved indication) | [PLACEHOLDER] |
| How long before results | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | Review at 8 weeks if no improvement (prescribing label) | [PLACEHOLDER] |
| Main side effects | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | Boxed warning for JAK class (nasopharyngitis, folliculitis, localized application site reactions [PLACEHOLDER]) | [PLACEHOLDER] |
| Use on face and folds | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | Non-steroidal formulation suitable without skin thinning; avoid direct contact with eyes/mucosa [PLACEHOLDER details] | [PLACEHOLDER] |
| Typical monthly cost | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] | [PLACEHOLDER] |
* Verified label excerpts reflect current manufacturer monographs and regulatory authorities. Rows with bracketed tokens denote subject areas requiring local pricing or individual prescriber context.
Treating the face, neck, and delicate skin folds
Skin on the face and folds is thin and sensitive. Long-term steroid creams can cause skin thinning in these areas. Non-steroid options help calm flares without thinning your skin. Always check with your doctor before treating delicate areas.
Before you see your doctor
Questions to ask your dermatologist
Take these precise clinical questions to your next appointment to clarify whether non-steroidal topical or systemic options align with your disease distribution and treatment history.
- Is my eczema currently classified as mild, moderate, or severe?
- Given that my flares occur on delicate areas (such as my eyelids, neck, or skin folds), should we switch from a steroid to a non-steroidal cream?
- How long should I use ruxolitinib cream before assessing whether it provides adequate itch and rash relief?
- What is the maximum body surface area I can safely treat with this prescription?
- If topical treatments do not sufficiently control my flares, at what stage should we explore systemic biologics or oral options?
Prescription and supply
Read about ruxolitinib cream for eczema →
Or check current pricing, authentic medicine supply, and how to order. Check availability and price →
Sources
Sources & Clinical References
- [1] Opzelura (ruxolitinib) cream 1.5% prescribing information, revised 06/2026.
- [2] American Academy of Dermatology (AAD) guidelines for the management of atopic dermatitis [PLACEHOLDER].
- [3] European consensus-based guideline for treatment of atopic eczema in adults and children [PLACEHOLDER].
About the formulation
‡ Unlike systemic immunosuppressants, topical JAK inhibition directly targets the local cutaneous Janus kinase signaling pathway (specifically JAK1 and JAK2), moderating cytokine-mediated inflammation without universal systemic suppression at approved dosages.
How we source information
All comparison metrics are extracted from official manufacturer monographs and peer-reviewed consensus statements. Do not alter dosage regimens without consulting your board-certified dermatologist.